Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer

We conducted a phase IIa, multi-centre, open label, single arm study (RADICAL; NCT01791985) of AZD4547 (a potent and selective inhibitor of Fibroblast Growth Factor Receptor (FGFR)-1, 2 and 3 receptor tyrosine kinases) administered with anastrozole or letrozole in estrogen receptor positive metastat...

Descripción completa

Detalles Bibliográficos
Autores principales: Coombes, R. C., Badman, P. D., Lozano-Kuehne, J. P., Liu, X., Macpherson, I. R., Zubairi, I., Baird, R. D., Rosenfeld, N., Garcia-Corbacho, J., Cresti, N., Plummer, R., Armstrong, A., Allerton, R., Landers, D., Nicholas, H., McLellan, L., Lim, A., Mouliere, F., Pardo, O. E., Ferguson, V., Seckl, M. J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9187670/
https://www.ncbi.nlm.nih.gov/pubmed/35688802
http://dx.doi.org/10.1038/s41467-022-30666-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9187670/
https://www.ncbi.nlm.nih.gov/pubmed/35688802
http://dx.doi.org/10.1038/s41467-022-30666-0

Ejemplares similares